172 related articles for article (PubMed ID: 36039910)
1. A phase II study of TAS-117 in patients with advanced solid tumors harboring germline
Rodón J; Funchain P; Laetsch TW; Arkenau HT; Hervieu A; Singer CF; Murciano-Goroff YR; Chawla SP; Anthony K; Yamamiya I; Liu M; Halim AB; Benhadji KA; Takahashi O; Delaloge S
Future Oncol; 2022 Sep; 18(30):3377-3387. PubMed ID: 36039910
[TBL] [Abstract][Full Text] [Related]
2. Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes.
Orloff MS; He X; Peterson C; Chen F; Chen JL; Mester JL; Eng C
Am J Hum Genet; 2013 Jan; 92(1):76-80. PubMed ID: 23246288
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.
Lee JB; Jung M; Beom SH; Kim GM; Kim HR; Choi HJ; Sohn JH; Ahn JB; Rha SY; Chung HC
Invest New Drugs; 2021 Oct; 39(5):1366-1374. PubMed ID: 33723724
[TBL] [Abstract][Full Text] [Related]
4. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway.
Zhou XP; Waite KA; Pilarski R; Hampel H; Fernandez MJ; Bos C; Dasouki M; Feldman GL; Greenberg LA; Ivanovich J; Matloff E; Patterson A; Pierpont ME; Russo D; Nassif NT; Eng C
Am J Hum Genet; 2003 Aug; 73(2):404-11. PubMed ID: 12844284
[TBL] [Abstract][Full Text] [Related]
5. Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations.
Yehia L; Ni Y; Sesock K; Niazi F; Fletcher B; Chen HJL; LaFramboise T; Eng C
PLoS Genet; 2018 Apr; 14(4):e1007352. PubMed ID: 29684080
[TBL] [Abstract][Full Text] [Related]
6. Toward Systems Pathology for PTEN Diagnostics.
Haddadi N; Travis G; Nassif NT; Simpson AM; Marsh DJ
Cold Spring Harb Perspect Med; 2020 May; 10(5):. PubMed ID: 31615872
[TBL] [Abstract][Full Text] [Related]
7. PTEN hamartoma tumor syndrome: clinical risk assessment and management protocol.
Ngeow J; Eng C
Methods; 2015 May; 77-78():11-9. PubMed ID: 25461771
[TBL] [Abstract][Full Text] [Related]
8. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.
Bennett KL; Mester J; Eng C
JAMA; 2010 Dec; 304(24):2724-31. PubMed ID: 21177507
[TBL] [Abstract][Full Text] [Related]
9. PTEN hamartoma tumor syndromes.
Blumenthal GM; Dennis PA
Eur J Hum Genet; 2008 Nov; 16(11):1289-300. PubMed ID: 18781191
[TBL] [Abstract][Full Text] [Related]
10. Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations.
Banneau G; Guedj M; MacGrogan G; de Mascarel I; Velasco V; Schiappa R; Bonadona V; David A; Dugast C; Gilbert-Dussardier B; Ingster O; Vabres P; Caux F; de Reynies A; Iggo R; Sevenet N; Bonnet F; Longy M
Breast Cancer Res; 2010; 12(4):R63. PubMed ID: 20712882
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment of cancer-prone germline PTEN mutant mice with low-dose rapamycin extends lifespan and delays tumour development.
Tibarewal P; Rathbone V; Constantinou G; Pearce W; Adil M; Varyova Z; Folkes L; Hampson A; Classen GAE; Alves A; Carvalho S; Scudamore CL; Vanhaesebroeck B
J Pathol; 2022 Dec; 258(4):382-394. PubMed ID: 36073856
[TBL] [Abstract][Full Text] [Related]
12. PTEN-opathies: from biological insights to evidence-based precision medicine.
Yehia L; Ngeow J; Eng C
J Clin Invest; 2019 Feb; 129(2):452-464. PubMed ID: 30614812
[TBL] [Abstract][Full Text] [Related]
13. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract][Full Text] [Related]
14. WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition.
Lee YR; Yehia L; Kishikawa T; Ni Y; Leach B; Zhang J; Panch N; Liu J; Wei W; Eng C; Pandolfi PP
N Engl J Med; 2020 May; 382(22):2103-2116. PubMed ID: 32459922
[TBL] [Abstract][Full Text] [Related]
15. PTEN lipid phosphatase activity and proper subcellular localization are necessary and sufficient for down-regulating AKT phosphorylation in the nucleus in Cowden syndrome.
He X; Saji M; Radhakrishnan D; Romigh T; Ngeow J; Yu Q; Wang Y; Ringel MD; Eng C
J Clin Endocrinol Metab; 2012 Nov; 97(11):E2179-87. PubMed ID: 22962422
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer risk and clinical implications for germline PTEN mutation carriers.
Ngeow J; Sesock K; Eng C
Breast Cancer Res Treat; 2017 Aug; 165(1):1-8. PubMed ID: 26700035
[TBL] [Abstract][Full Text] [Related]
17. Cerebellar phenotypes in germline PTEN mutation carriers.
Gambini D; Ferrero S; Bulfamante G; Pisani L; Corbo M; Kuhn E
Neuropathol Appl Neurobiol; 2024 Apr; 50(2):e12970. PubMed ID: 38504418
[TBL] [Abstract][Full Text] [Related]
18. [Cowden disease and the PTEN gene: a successfully clinical and biological combined approach].
Longy M
Bull Cancer; 2001 Dec; 88(12):1153-8. PubMed ID: 11792608
[TBL] [Abstract][Full Text] [Related]
19. A novel loss-of-function mutation (N48K) in the PTEN gene in a Spanish patient with Cowden disease.
Vega A; Torres J; Torres M; Cameselle-Teijeiro J; Macia M; Carracedo A; Pulido R
J Invest Dermatol; 2003 Dec; 121(6):1356-9. PubMed ID: 14675182
[TBL] [Abstract][Full Text] [Related]
20. A novel deleterious PTEN mutation in a patient with early-onset bilateral breast cancer.
Pradella LM; Evangelisti C; Ligorio C; Ceccarelli C; Neri I; Zuntini R; Amato LB; Ferrari S; Martelli AM; Gasparre G; Turchetti D
BMC Cancer; 2014 Feb; 14():70. PubMed ID: 24498881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
